{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:03:30Z","timestamp":1784901810320,"version":"3.55.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiandrogen therapy is a cornerstone in managing female pattern hair loss (FPHL), yet comparative efficacy data between commonly used agents such as spironolactone and bicalutamide are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of bicalutamide (50\u2005mg day\u20131) vs. spironolactone (100\u2005mg day\u20131) monotherapy in women with FPHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, parallel-group clinical trial was conducted at a tertiary care centre in India between February 2024 and March 2025. In total, 204 women aged 18\u201350\u2005years with Sinclair grade II\u2013V FPHL were randomized. Participants received either spironolactone 100\u2005mg day\u20131 or bicalutamide 50\u2005mg day\u20131 orally for 24 weeks. Trichoscopic assessments were performed at baseline and 24 weeks. Primary outcomes were changes in hair density and shaft diameter at two fixed scalp points [12\u2005cm (frontal) and 24\u2005cm (vertex) from the glabella]. Secondary outcomes included global photographic assessment, reduction in Sinclair hair shedding score and safety profile. The trial was registered with the Clinical Trials Registry of India (CTRI\/2024\/01\/062101).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 204 randomized participants, 188 (92.2%) completed the trial. The mean (SD) increase in hair count at the frontal site was 5.05 (3.61) hairs cm\u20132 in the bicalutamide group vs. 3.13 (2.62) hairs cm\u20132 in the spironolactone group [mean difference 1.92; 95% confidence interval (CI) 1.01\u20132.62; P &amp;lt; 0.001]. At the vertex site, the increase was 6.32 (9.38) vs. 3.06 (10.76) hairs cm\u20132, respectively (mean difference 3.26; 95% CI 0.35\u20136.08; P = 0.028). Hair shaft diameter increased more with bicalutamide at both sites [mean difference 2.87\u2005\u03bcm; 95% CI 2.12\u20133.32 (frontal) and 2.10\u20133.36\u2005\u03bcm (vertex); P &amp;lt; 0.001 for both]. Adverse events were reported in 18.6% of spironolactone-treated and 11.7% of bicalutamide-treated participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bicalutamide produced greater trichoscopic improvements than spironolactone; however, no significant between-group differences were observed in clinical endpoints. Limitations include a short follow-up period, single-centre design and per-protocol analysis, which may limit generalizability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag099","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:40:43Z","timestamp":1771936843000},"page":"1406-1411","source":"Crossref","is-referenced-by-count":0,"title":["Spironolactone vs. bicalutamide in female pattern hair loss: a randomized clinical trial"],"prefix":"10.1093","volume":"51","author":[{"given":"Abhijeet Kumar","family":"Jha","sequence":"first","affiliation":[{"name":"Department of Dermatology & STD, Patna Medical College & Hospital , Patna ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Zeeshan","sequence":"additional","affiliation":[{"name":"Department of Dermatology & STD, Patna Medical College & Hospital , Patna ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Dermatology & STD, Patna Medical College & Hospital , Patna ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balachandra S","family":"Ankad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, S Nijalingappa Medical College , Bagalkot ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026072409163743900_llag099-B1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/0974-7753.114709","article-title":"Finasteride 5\u2005mg\/day treatment of patterned hair loss in normo-androgenetic postmenopausal women","volume":"5","author":"Oliveira-Soares","year":"2013","journal-title":"Int J Trichology"},{"key":"2026072409163743900_llag099-B2","first-page":"414","article-title":"Side effects related to 5\u03b1-reductase inhibitor treatment of hair loss in women: a review","volume":"15","author":"Seale","year":"2016","journal-title":"J\u00a0Drugs Dermatol"},{"key":"2026072409163743900_llag099-B3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-020-00557-5","article-title":"Hormonal contraceptives and dermatology","volume":"22","author":"Williams","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2026072409163743900_llag099-B4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2025.04.074","article-title":"Antiandrogen therapy for the treatment of female pattern hair loss: a clinical review of current and emerging therapies","volume":"93","author":"Ong","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026072409163743900_llag099-B5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","article-title":"Treatment of female pattern hair loss with oral antiandrogens","volume":"152","author":"Sinclair","year":"2005","journal-title":"Br J Dermatol"},{"key":"2026072409163743900_llag099-B6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0531-5565(02)00093-1","article-title":"Molecular mechanisms of androgenetic alopecia","volume":"37","author":"Tr\u00fceb","year":"2002","journal-title":"Exp Gerontol"},{"key":"2026072409163743900_llag099-B7","first-page":"951","volume-title":"Pharmacology and Therapeutics: Principles to Practice","author":"Holstein","year":"2008","edition":"1st edn"},{"key":"2026072409163743900_llag099-B8","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1111\/jocd.14773","article-title":"Bicalutamide and the new perspectives for female pattern hair loss treatment: what dermatologists should know","volume":"21","author":"Carvalho","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"2026072409163743900_llag099-B9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ajd.14306","article-title":"Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: a retrospective comparative study","volume":"65","author":"Jha","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026072409163743900_llag099-B10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjd.13873","article-title":"Hair shedding in women: how much is too much?","volume":"173","author":"Sinclair","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026072409163743900_llag099-B11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jaad.2020.03.034","article-title":"Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients","volume":"83","author":"Ismail","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026072409163743900_llag099-B12","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.jaad.2020.04.054","article-title":"Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss","volume":"83","author":"Fernandez-Nieto","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026072409163743900_llag099-B13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jdin.2024.12.002","article-title":"Bicalutamide 25\u2005mg combined with minoxidil 1\u2005mg versus minoxidil 1\u2005mg for female pattern hair loss: a randomized double-blind clinical trial","volume":"19","author":"da Silva Lib\u00f3rio","year":"2025","journal-title":"JAAD Int"},{"key":"2026072409163743900_llag099-B14","first-page":"217","article-title":"Evidence for use of antiandrogens in female pattern hair loss","volume":"15","author":"Famenini","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"2026072409163743900_llag099-B15","first-page":"77","article-title":"Safety and monitoring of antiandrogen use in women","volume":"40","author":"Donovan","year":"2022","journal-title":"Dermatol Clin"},{"key":"2026072409163743900_llag099-B16","first-page":"65","article-title":"Advances in understanding of female pattern hair loss","volume":"9","author":"Ramos","year":"2020","journal-title":"F1000Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag099\/67118359\/llag099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1406\/67118359\/llag099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1406\/67118359\/llag099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:16:43Z","timestamp":1784899003000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/8\/1406\/8498161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag099","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,2,25]]}}}